ClinicalTrials.gg
RecruitingNCT05723588TMS-STOPUpdated Nov 19, 2026

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD

A Phase 2 interventional study of active repetitive transcranial magnetic stimulation and sham repetitive transcranial magnetic stimulation in Tobacco Use Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tobacco Use Disorder by VA Office of Research and Development — 5 open to participants now, 6 under way, none of them phase 3. Tobacco Use Disorder · VA Office of Research and Development.

Planned enrollment
13th of 16
50 · median 128
Started
2023
with 1 other
Phase 2
4 of 17
1 open now
Registered
13th of 17
by date

Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 13th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 17 studies in Tobacco Use Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tobacco Use Disorder by VA Office of Research and Development, or all of them as a file.
02

Study summary

Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.

Read the detailed description

Tobacco use remains the number one preventable cause of death in the United States. Unfortunately, individuals with mental health conditions are disproportionately affected. Tobacco use is also high among US Veterans, and those who have experienced trauma are even more likely to smoke. Successful quitting is especially difficult for individuals who develop posttraumatic stress disorder (PTSD). Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Neuroimaging techniques such as resting-state functional magnetic resonance imaging (rs-fMRI) have provided insight into the neurocircuitry of tobacco use disorder (TUD) and successful quit attempts. Interventions that modulate the neural systems underlying TUD, such as repetitive transcranial magnetic stimulation (rTMS), may be critical to improving clinical outcomes. Indeed, the US Food and Drug Administration (FDA) recently cleared a form of rTMS as a short-term smoking cessation treatment in adults. However, most clinical trials on rTMS for smoking cessation have been conducted in civilian samples and have excluded individuals with psychiatric conditions. To improve smoking cessation treatment options for Veterans with PTSD, it is critical to evaluate novel brain stimulation methods such as rTMS in this vulnerable population. Furthermore, the development of neuroscience-informed techniques to enhance rTMS such as neuronavigation based on rs-fMRI is critical to individualizing rTMS for smoking cessation and understanding mechanisms of action. The application of neuroimaging to develop personalized rTMS targets to precisely modulate targeted underlying neurocircuitry has been successfully applied to the treatment of major depressive disorder (MDD). Similar methodology has been demonstrated successfully for smoking cessation by the candidate's mentors, but this work was completed in a sample of civilian participants making a quit attempt who did not have psychiatric illness. To fill these knowledge gaps, the proposed research aims to develop feasibility data for the therapeutic application individualized neuronavigated rTMS for Veterans with PTSD attempting to quit smoking. Using a feasibility randomized controlled trial (RCT) design, eligible Veterans with PTSD (n=50) seeking smoking cessation will receive rs-fMRI before and after a 5-day course of neuronavigated rTMS the week prior to their quit date, in conjunction with nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT). The scientific aims of the study are to evaluate feasibility of treatment delivery procedures, develop preliminary effect size estimates, and demonstrate target engagement of the intervention within neural networks critical to TUD.

03

Conditions studied

  • Tobacco Use Disorder

Keywords

  • Tobacco use cessation
  • Veterans
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a US Veteran
  • Meets criteria for tobacco use disorder
  • Is between the ages of 18 and 75
  • Smokes an average of 10 cigarettes per day for the past 6 months, with carbon monoxide (CO) level > 6 ppm
  • Is willing to attempt smoking cessation
  • Meets DSM-5 criteria for current PTSD diagnosis
  • Speaks, reads and writes English
  • Is willing to sign a Duke consent for those portions of the study that occur at Duke
  • Has been stable on psychotropic medications for at least three months

Exclusion criteria

Exclusion Criteria:

  • Has had a substance use disorder other than tobacco in the preceding 3 months
  • Has a history of myocardial infarction in the past 6 months or has another to NRT
  • Has a contraindication to TMS or MRI

    • Personal or family history of a seizures or epilepsy
    • History of neurological condition that increases the risk of seizures including stroke or , cerebral aneurysm, or severe traumatic brain injury from a penetrating head injury, loss of consciousness > 20 minutes at time of traumatic injury, requiring an anticonvulsant medication for seizures, and/or found to have encephalomalacia on baseline MRI
    • Structural brain lesion, or prior brain surgery
    • Ferromagnetic metal in head (including shrapnel)
    • Implanted devices that may be affected by MRI or TMS (pacemaker, medication pump, cochlear implant, implanted deep brain stimulator)
    • Is pregnant (to be determined at Duke)
  • Is unable to complete study procedures
  • Is currently prescribed bupropion and/or varenicline
  • Uses other forms of nicotine such as cigars, pipes, chewing tobacco, or vaping
  • Is unable to provide due to a major neurocognitive disorder or other reason
  • Meets criteria for a primary psychotic disorder or current manic episode
  • Is currently imprisoned or psychiatrically hospitalized
  • Has previously received rTMS
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    active rTMS

    Participants assigned to this group will receive active repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.

    Device: active repetitive transcranial magnetic stimulation · Behavioral: cognitive behavioral therapy for smoking cessation · Drug: nicotine replacement therapy

  • Sham comparator
    sham rTMS

    Participants assigned to this group will receive sham repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.

    Device: sham repetitive transcranial magnetic stimulation · Behavioral: cognitive behavioral therapy for smoking cessation · Drug: nicotine replacement therapy

Interventions

  • Deviceactive repetitive transcranial magnetic stimulation

    Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.

    Also known as: active rTMS

  • Devicesham repetitive transcranial magnetic stimulation

    Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.

    Also known as: sham rTMS

  • Behavioralcognitive behavioral therapy for smoking cessation

    All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.

    Also known as: CBT

  • Drugnicotine replacement therapy

    All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a "rescue" method such as nicotine lozenge or nicotine gum.

    Also known as: NRT, nicotine patch, nicotine gum, nicotine lozenges

06

What researchers measure

Primary outcomes

  1. Feasibility as measured by number of participants recruited

    Number of participants recruited will serve as a measure of study feasibility. Target enrollment is 50 participants.

    Time frame: At consent

  2. Feasibility as measured by the percent of participants who complete the study

    The percent of participants who complete the 3-month follow-up visit will serve as a measure of treatment feasibility. 80% retention will be the cut point.

    Time frame: 3-month follow-up

  3. Number of participants with self-reported and bioverified abstinence from smoking

    Effectiveness of the intervention will be measured by the number of participants who self-report 7-day point prevalence at the end of treatment, and self-report is bioverified by exhaled carbon monoxide.

    Time frame: End of treatment, about five weeks after beginning study

  4. Number of participants with self-reported and bioverified abstinence from smoking

    Effectiveness of the intervention will be measured by the number of participants who self-report 7-day point prevalence at the 3-month follow-up visit, and self-report is bioverified by salivary cotinine.

    Time frame: 3-month follow-up

Secondary outcomes

  1. Average number of cigarettes smoked per day in past week

    Participants will self-report the number of cigarettes they have smoked per day in the past week.

    Time frame: End of treatment, about five weeks after beginning study

  2. Average number of cigarettes smoked per day in past week

    Participants will self-report the number of cigarettes they have smoked per day in the past week.

    Time frame: 3-month follow-up

  3. Self-reported withdrawal symptoms

    Participants will self-report withdrawal symptoms on the Minnesota Nicotine Withdrawal Scale. Scores on this scale range from 0 to 36, with higher scores indicating higher severity of withdrawal symptoms.

    Time frame: End of treatment, about five weeks after beginning study

  4. Self-reported withdrawal symptoms

    Participants will self-report withdrawal symptoms on the Minnesota Nicotine Withdrawal Scale. Scores on this scale range from 0 to 36, with higher scores indicating higher severity of withdrawal symptoms.

    Time frame: 3-month follow-up

  5. Self-report of craving based on Questionnaire of Smoking Urges

    Participants will self-report cravings for tobacco on the Questionnaire of Smoking Urges. Scores on this scale range from 0 to 60, with higher scores indicating higher smoking craving.

    Time frame: End of treatment, about five weeks after beginning study

  6. Self-report of craving based on Questionnaire of Smoking Urges

    Participants will self-report cravings for tobacco on the Questionnaire of Smoking Urges. Scores on this scale range from 0 to 60, with higher scores indicating higher smoking craving.

    Time frame: 3-month follow-up

  7. Number of participants who report relapse to smoking

    Measured by self-report, smoking relapse is defined as smoking 5 or more cigarettes per day for 3 consecutive days.

    Time frame: End of treatment, about five weeks after beginning study

  8. Number of participants who report relapse to smoking

    Measured by self-report, smoking relapse is defined as smoking 5 or more cigarettes per day for 3 consecutive days.

    Time frame: 3-month follow-up

  9. Functional network connectivity changes

    Comparison of functional network connectivity (FNC) changes between the postcentral gyrus cortical rTMS target and right posterior insula using magnetic resonance imaging before and after the rTMS course

    Time frame: End of repetitive transcranial magnetic stimulation treatment, about three weeks after beginning study

  10. Neuroimaging correlates to tobacco use

    Correlation of resting state functional connectivity changes pre- vs post-rTMS course and the change in the number of cigarettes smoked in the past 24 hours

    Time frame: End of repetitive transcranial magnetic stimulation treatment, about three weeks after beginning study

  11. Self-report of craving based on Urge to Smoke Scale

    Participants will report smoking craving using this single-item measure. Scores range from 0 to 100 with higher scores indicating higher smoking craving.

    Time frame: End of treatment visit, about five weeks after beginning study

  12. Self-report of craving based on Urge to Smoke Scale

    Participants will report smoking craving using this single-item measure. Scores range from 0 to 100 with higher scores indicating higher smoking craving.

    Time frame: 3-month follow-up

  13. Self-report of craving based on Urge to Smoke Scale

    Participants will self-report craving on the single-item Urge to Smoke Scale. Scores on this scale range from 0 to 100, with higher scores indicating higher cravings to smoke.

    Time frame: End of treatment, about five weeks after beginning study

  14. Self-report of craving based on Urge to Smoke Scale

    Participants will self-report craving on the single-item Urge to Smoke Scale. Scores on this scale range from 0 to 100, with higher scores indicating higher cravings to smoke.

    Time frame: 3-month follow-up

Other outcomes

  1. Self-report posttraumatic stress disorder (PTSD) symptoms

    Participants will self-report PTSD symptoms on the PTSD Checklist - 5. Scores on this measure range from 0 to 80, with higher scores indicating higher severity of PTSD symptoms.

    Time frame: End of treatment, about five weeks after beginning study

  2. Self-report posttraumatic stress disorder (PTSD) symptoms

    Participants will self-report PTSD symptoms on the PTSD Checklist - 5. Scores on this measure range from 0 to 80, with higher scores indicating higher severity of PTSD symptoms.

    Time frame: 3-month follow-up

  3. Self-reported depressive symptoms

    Participants will self-report depression symptoms on the Inventory of Depressive Symptomatology. Scores on this scale range from 0 to 90, with higher scores indicating higher depression symptom severity.

    Time frame: End of treatment, about five weeks after beginning study

  4. Self-reported depressive symptoms

    Participants will self-report depression symptoms on the Beck Depression Inventory - 2. Scores on this scale range from 0 to 63, with higher scores indicating higher depression symptom severity.

    Time frame: 3-month follow-up

  5. Severity of baseline smoking on abstinence

    Measured by self-report, plan to evaluate degree of baseline smoking severity (daily cigarettes) on smoking abstinence at end-of-treatment

    Time frame: End of treatment, about five weeks after beginning study

  6. Severity of baseline smoking on abstinence

    Measured by self-report, plan to evaluate degree of baseline smoking severity (daily cigarettes) on smoking abstinence at 3-month follow-up

    Time frame: 3-month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Of 37 non-industry phase 2 interventional studies under Tobacco Use Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 46. This study's planned 48 months is above that.

Counting every sponsor, half of 41 studies reached it within 35 months; a quarter within 19 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 10, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05723588
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Oct 31, 2023
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Jonathan R Young, MD
Contact
jonathan.young14@va.gov
(919) 286-0411
Angela C Kirby, MS
Contact
angela.kirby@va.gov
(919) 286-0411 ext. 7456
Jonathan R Young, MD
principal investigator · Durham VA Medical Center, Durham, NC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion